Athlete GLP-1 Body Composition & Power Modeler

Athlete & Drug Protocol

Sport Archetype Presets

Peptide Generation / Mechanism Gen 2: Tirzepatide Dual GIP/GLP-1 agonist: improved appetite suppression with ~25% lean loss fraction in clinical cohorts. Starting Weight 315 lbs (142.9 kg) Baseline Body Fat % 28.0% Starting Lean Mass: 226.8 lbs · Fat Mass: 88.2 lbs Target Caloric Deficit / Speed Moderate (-750 kcal/day) Target loss rate: ~1.5 lbs/week. Extreme deficits spike muscle protein breakdown. Protocol Duration 16 Weeks Hypertrophy / Resistance Training 4 Sessions / wk (High Intensity) Daily Protein Intake 2.2 g/kg (High Preservation) ≥2.0 g/kg stimulates muscle protein synthesis during negative energy balance. Baseline 1RM Squat / Anchor Force 520 lbs

Projected Final Weight 291.6 lbs Total Loss: -23.4 lbs

Lean Mass Spared 223.1 lbs Muscle Lost: -3.7 lbs (16%)

Fat Mass Shed 68.5 lbs Final BF%: 23.5%

Power-to-Weight Ratio +6.4% Est. 40yd: -0.11s

Body Mass Breakdown Over Time (Lean vs Fat Mass)

Total Weight

Lean Tissue

Fat Mass

Week	Dose Titration	Total Weight	Lean Mass	Fat Mass	Body Fat %	1RM Strength	Peak Momentum

Athletic Trade-Offs & Sarcopenia Risk Low Muscle Risk

Lean Mass Loss Ratio: 15.8% of lost weight
Absolute Anchor Force (Estimated 1RM): 506 lbs (-14 lbs / -2.7%)
Momentum at 7.0 m/s Sprint: 926 N·s (-74 N·s / -7.4%)
Power-to-Mass Index ($P/M$): 3.83 W/kg (+5.2%)

Peptide & Nutrition Countermeasures

Protein Distribution: 314 g/day (~4x 78g boluses)
Leucine Threshold: 3.5g per meal for mTOR activation
Hydration / GI Strategy: Electrolytes + slow-gastric transit buffers
Pipeline Advantage: Dual GIP synergy preserves thermogenesis

Model calibrated against STEP-1, SURMOUNT-1, and athlete resistance trials.

Why GLP-1s Present a Double-Edged Sword for Athletes

As highlighted by sports physiologists, weight loss medications can benefit athletes in weight-bearing or collision sports who need to trim redundant adipose mass for joint longevity, cardiovascular work capacity, and sprint acceleration. However, in unmonitored caloric restriction, up to 35%–40% of weight lost on early GLP-1 receptor agonists can come from lean skeletal muscle.

For an NFL offensive tackle or rugby forward, lean muscle mass is not just aesthetic—it is the physical ballast required to absorb 2,000+ Newtons of impact force in the trenches. Losing 15 pounds of contractile muscle compromises anchor strength and rotational torso stiffness.

How Next-Generation Peptides Address Muscle Wasting

Gen 1 Semaglutide: Monotherapy. Substantial weight loss (~15%), but higher lean mass attrition without rigorous resistance protocols.
Gen 2 Tirzepatide: Dual GLP-1/GIP co-agonism enhances lipid oxidation while dampening nausea and appetite swings.
Gen 3 Retatrutide / CagriSema: Tri-agonists adding glucagon receptor activity, dramatically ramping energy expenditure with enhanced metabolic rate retention.
Gen 4 Pipeline GLP-1 + Myostatin / Activin Inhibitors: Clinical candidates (e.g. Bimagrumab, Taldefgrobep alfa) designed to simultaneously incinerate adipose tissue while preserving or even augmenting hypertrophic muscle fibers.